Kyverna Therapeutics Inc shares rose as much as 59 percent in early trading on Thursday after its expanded US initial public offering (IPO) raised US$319 million, as drug developers continue to receive a warm welcome from new investors.
Emeryville, California-based Kyverna’s shares gave back some of those gains to end the session at US$30 each in New York, 36 percent above the IPO price of US$22.
At that price, the Bain Capital LP-backed biotechnology company has a market value of about US$1.2 billion.
Photo: Reuters
The opening surge was the biggest for a company raising more than US$100 million in an IPO since Cava Group Inc’s US$365 million debut in June last year, according to data compiled by Bloomberg.
Kyverna had a tough time deciding who to allocate shares to given “very large mutual funds were willing to come into the story and wanted to be part of” the deal, chief executive officer Peter Maag said in an interview. The IPO was about “20-times oversubscribed,” he said.
“This is a tremendous outcome for the organization as it gives us the capital to execute our clinical trial program,” Maag said.
The funds are expected to provide a runway into 2026 and set it up for potential pivotal trials, he said.
The strong results continue a streak of therapeutics companies drawing heightened investor demand.
The offering is the second-largest for a drug developer this year, after cancer-focused CG Oncology Inc raised US$437 million two weeks ago, according to data compiled by Bloomberg. Its shares have more than doubled since its debut.
Kyverna’s lead medicine is a CAR T-cell therapy for autoimmune diseases in rheumatology and neurology. Bain Capital, Gilead Sciences Inc, Vida Ventures LLC and Westlake BioPartners LLC are among Kyverna’s largest investors, according to the company’s filings with the US Securities and Exchange Commission.
Kyverna is part of a busy week for US IPOs that includes American Healthcare REIT Inc, which raised US$672 million and is up nearly 10 percent, and a Mexican grocery chain. Also in biotech, Moderna Inc-backed Metagenomi Inc’s offering was slated to price later on Thursday.
HSBC Innovation Banking managing director Jonathan Norris expects about 25 venture capital-backed biotech IPOs in the US and Europe this year.
There will be “more later-stage than earlier companies with a focus on drugs that have opportunities for catalysts in the near-term,” Norris said.
Drug developers have been actively raising cash through sales of new shares to public investors this year.
The industry has raised nearly US$5 billion via follow-on offerings, data compiled by Bloomberg showed, more than double the amount seen through Feb. 7 last year.
PATENTS: MediaTek Inc said it would not comment on ongoing legal cases, but does not expect the legal action by Huawei to affect its business operations Smartphone integrated chips designer MediaTek Inc (聯發科) on Friday said that a lawsuit filed by Chinese smartphone brand Huawei Technologies Co (華為) over alleged patent infringements would have little impact on its operations. In an announcement posted on the Taiwan Stock Exchange, MediaTek said that it would not comment on an ongoing legal case. However, the company said that Huawei’s legal action would have little impact on its operations. MediaTek’s statement came after China-based PRIP Research said on Thursday that Huawei filed a lawsuit with a Chinese district court claiming that MediaTek infringed on its patents. The infringement mentioned in the lawsuit likely involved
Taipei is today suspending work, classes and its US$2.4 trillion stock market as Typhoon Gaemi approaches Taiwan with strong winds and heavy rain. The nation is not conducting securities, currency or fixed income trading, statements from its stock and currency exchanges said. Authorities had yesterday issued a warning that the storm could affect people on land and canceled some ship crossings and domestic flights. Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) expects its local chipmaking fabs to maintain normal production, the company said in an e-mailed statement. The main chipmaker for Apple Inc and Nvidia Corp said it has activated routine typhoon alert
GROWTH: TSMC increased its projected revenue growth for this year to more than 25 percent, citing stronger-than-expected demand for AI devices and smartphones The Taiwan Institute of Economic Research (TIER, 台灣經濟研究院) yesterday raised its forecast for Taiwan’s GDP growth this year from 3.29 percent to 3.85 percent, as exports and private investment recovered faster than it predicted three months ago. The Taipei-based think tank also expects that Taiwan would see a 8.19 percent increase in exports this year, better than the 7.55 percent it projected in April, as US technology giants spent more money on artificial intelligence (AI) infrastructure and development. “There will be more AI servers going forward, but it remains to be seen if the momentum would extend to personal computers, smartphones and
Catastrophic computer outages caused by a software update from one company have once again exposed the dangers of global technological dependence on a handful of players, experts said on Friday. A flawed update sent out by the little-known security firm CrowdStrike Holdings Inc brought airlines, TV stations and myriad other aspects of daily life to a standstill. The outages affected companies or individuals that use CrowdStrike on the Microsoft Inc’s Windows platform. When they applied the update, the incompatible software crashed computers into a frozen state known as the “blue screen of death.” “Today CrowdStrike has become a household name, but not in